Article
Persister cell phenotypes contribute to poor patient outcomes after neoadjuvant chemotherapy in PDAC.
Nature cancer - 1 Sept 2023
Zhou Xu, An Jingyu, Kurilov Roma, Brors Benedikt, Hu Kai, Peccerella Teresa, Roessler Stephanie, Pfütze Katrin, Schulz Angela, Wolf Stephan, Hohmann Nicolas, Theile Dirk, Sauter Max, Burhenne Jürgen, Ei Shigenori, Heger Ulrike, Strobel Oliver, Barry Simon T, Springfeld Christoph, Tjaden Christine, Bergmann Frank, Büchler Markus, Hackert Thilo, Fortunato Franco, Neoptolemos John P, Bailey Peter
Abstract excerpt
Neoadjuvant chemotherapy can improve the survival of individuals with borderline and unresectable pancreatic ductal adenocarcinoma; however, heterogeneous responses to chemotherapy remain a significant clinical challenge. Here, we performed RNA sequencing (n = 97) and multiplexed immunofluorescence (n = 122) on chemo-naive and postchemotherapy (post-CTX) resected patient samples (chemoradiotherapy excluded) to...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
